AIM CONCEPT INTEGRATION
4th Year MBBS • ENDOCRINE + REPRODUCTION
Topic 23 — Breast Lump and Breast Cancer: Benign Disease, Investigation, Management and Prevention
Connect pathology, clinical assessment, imaging, receptor biology, treatment and prevention into one rapid-revision pathway.
KMU scope and concept-integration structure aligned with the supplied instructions. :contentReference[oaicite:0]{index=0}
1. THE TOPIC IN ONE CONNECTED FLOW
A breast lump may represent benign hormonal or structural change, a benign tumor or carcinoma. The key is to connect the biological process with the clinical appearance, confirm the diagnosis through triple assessment, then use stage and receptor status to guide treatment while screening and prevention act at earlier points in the disease pathway.
Risk / Starting Point
Age, inherited risk, hormonal exposure or benign breast change
→
Pathological Change
Benign proliferation or malignant epithelial transformation
→
Tissue Behaviour
Circumscribed benign growth or stromal invasion and spread
→
Clinical Presentation
Lump, nipple change, skin tethering or regional nodes
→
Diagnosis
Clinical assessment + imaging + tissue diagnosis
→
Treatment / Prevention
Stage + ER/PR/HER2 guide therapy; screening detects earlier disease
→
Outcome
Local control, reduced recurrence or complications requiring rehabilitation
2. KEY CLINICAL CONNECTIONS
Morphology → Clinical Clue
Fibroadenoma
→
circumscribed stromal growth
→
smooth, firm, mobile lump
→
circumscribed stromal growth
→
smooth, firm, mobile lump
Intraductal papilloma
→
fragile fibrovascular papillae
→
serous or bloody nipple discharge
→
fragile fibrovascular papillae
→
serous or bloody nipple discharge
Clinical Sign → Mechanism → Diagnosis
Tumor-associated fibrosis
→
duct/supporting-tissue traction
→
nipple retraction or skin tethering
→
duct/supporting-tissue traction
→
nipple retraction or skin tethering
Dermal lymphatic obstruction
→
skin edema
→
peau d’orange
→
skin edema
→
peau d’orange
Tumor Biology → Treatment
ER/PR positive
→
estrogen-dependent growth
→
endocrine therapy
→
estrogen-dependent growth
→
endocrine therapy
Tamoxifen
→
estrogen-receptor blockade in breast
→
reduced tumor stimulation
→
caution: thromboembolism/endometrial stimulation
→
estrogen-receptor blockade in breast
→
reduced tumor stimulation
→
caution: thromboembolism/endometrial stimulation
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Fibrocystic change → cyst rupture and epithelial/stromal change → fibrosis may produce a firm irregular breast texture.
Adenosis → increased acini within a lobule → stromal sclerosis may distort the lesion while preserving basic lobular architecture.
⭐ Suspicious breast lesion → clinical examination + ultrasound/mammography + tissue diagnosis → concordant triple assessment establishes the diagnosis.
Ultrasound → excellent cystic/solid characterization; mammography → detects distortion and microcalcification → both complement clinical assessment.
⭐ Invasive carcinoma → basement-membrane breach → lymphatic or blood spread → nodal/distant involvement increases stage and worsens prognosis.
Stage + receptor status → determine local and systemic treatment → surgery/radiotherapy control local disease while systemic therapy treats occult or metastatic disease.
⭐ SERMs in high-risk women → reduced estrogen-driven breast proliferation → reduced risk of ER-positive cancer, balanced against drug-related harms.
Prevention pathway → risk reduction before disease + screening for early detection + rehabilitation after treatment → lower disease burden and disability.
AIM Exam Trap: Mammographic screening detects disease before symptoms develop, so it is secondary prevention; preventive SERMs or risk-reducing surgery given before cancer develops are forms of primary prevention.